Cargando…

Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure

BACKGROUND: The Global Research on the Impact of Dermatological Diseases (GRIDD) team is developing the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure of the impact of dermatological conditions on the patient’s life, in partnership with patients. To develop PRIDD, we conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Pattinson, Rachael, Trialonis-Suthakharan, Nirohshah, Hewitt, Rachael M., Valencia López, Maria José, Tahmasebi Gandomkari, Nasim, Austin, Jennifer, FitzGerald, Allison, Courtier, Nick, Augustin, Matthias, Bundy, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196461/
https://www.ncbi.nlm.nih.gov/pubmed/37215711
http://dx.doi.org/10.3389/fmed.2023.1020523
_version_ 1785044359608008704
author Pattinson, Rachael
Trialonis-Suthakharan, Nirohshah
Hewitt, Rachael M.
Valencia López, Maria José
Tahmasebi Gandomkari, Nasim
Austin, Jennifer
FitzGerald, Allison
Courtier, Nick
Augustin, Matthias
Bundy, Chris
author_facet Pattinson, Rachael
Trialonis-Suthakharan, Nirohshah
Hewitt, Rachael M.
Valencia López, Maria José
Tahmasebi Gandomkari, Nasim
Austin, Jennifer
FitzGerald, Allison
Courtier, Nick
Augustin, Matthias
Bundy, Chris
author_sort Pattinson, Rachael
collection PubMed
description BACKGROUND: The Global Research on the Impact of Dermatological Diseases (GRIDD) team is developing the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure of the impact of dermatological conditions on the patient’s life, in partnership with patients. To develop PRIDD, we conducted a systematic review, followed by a qualitative interview study with 68 patients worldwide and subsequently a global Delphi survey of 1,154 patients to ensure PRIDD items were meaningful and important to patients. OBJECTIVE: To pilot test PRIDD with patients with dermatological conditions, focusing on its content validity (comprehensiveness, comprehensibility, and relevance), acceptability, and feasibility. METHODS: We conducted a theory-led qualitative study using the Three-Step Test-Interview method of cognitive interviewing. Three rounds of semi-structured interviews were conducted online. Adults (≥ 18 years) living with a dermatological condition and who spoke English sufficiently to take part in the interview were recruited through the International Alliance of Dermatology Patient Organizations’ (GlobalSkin) global membership network. The topic guide met the gold-standard COSMIN (Consensus-based Standards for the Selection of Health Measurement Instruments) standards for cognitive interviewing. Analysis followed the thematic analytical model of cognitive interviewing. RESULTS: Twelve people (58% male) representing six dermatological conditions from four countries participated. Overall, patients found PRIDD to be comprehensible, comprehensive, relevant, acceptable, and feasible. Participants were able to discern the conceptual framework domains from the items. Feedback resulted in: the recall period being extended from 1 week to 1 month; removal of the ‘not relevant’ response option; and changes to the instructions and item ordering and wording to improve clarity and increase respondents’ confidence in their ability to respond. These evidence-based adjustments resulted in a 26-item version of PRIDD. CONCLUSION: This study met the gold-standard COSMIN criteria for the pilot testing of health measurement instruments. The data triangulated our previous findings, in particular the conceptual framework of impact. Our findings illuminate how patients understand and respond to PRIDD and other patient-reported measurement instruments. The results of comprehensibility, comprehensiveness, relevance, acceptability, and feasibility of PRIDD provide evidence of content validity from the target population. The next step in the development and validation of PRIDD is psychometric testing.
format Online
Article
Text
id pubmed-10196461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101964612023-05-20 Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure Pattinson, Rachael Trialonis-Suthakharan, Nirohshah Hewitt, Rachael M. Valencia López, Maria José Tahmasebi Gandomkari, Nasim Austin, Jennifer FitzGerald, Allison Courtier, Nick Augustin, Matthias Bundy, Chris Front Med (Lausanne) Medicine BACKGROUND: The Global Research on the Impact of Dermatological Diseases (GRIDD) team is developing the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure of the impact of dermatological conditions on the patient’s life, in partnership with patients. To develop PRIDD, we conducted a systematic review, followed by a qualitative interview study with 68 patients worldwide and subsequently a global Delphi survey of 1,154 patients to ensure PRIDD items were meaningful and important to patients. OBJECTIVE: To pilot test PRIDD with patients with dermatological conditions, focusing on its content validity (comprehensiveness, comprehensibility, and relevance), acceptability, and feasibility. METHODS: We conducted a theory-led qualitative study using the Three-Step Test-Interview method of cognitive interviewing. Three rounds of semi-structured interviews were conducted online. Adults (≥ 18 years) living with a dermatological condition and who spoke English sufficiently to take part in the interview were recruited through the International Alliance of Dermatology Patient Organizations’ (GlobalSkin) global membership network. The topic guide met the gold-standard COSMIN (Consensus-based Standards for the Selection of Health Measurement Instruments) standards for cognitive interviewing. Analysis followed the thematic analytical model of cognitive interviewing. RESULTS: Twelve people (58% male) representing six dermatological conditions from four countries participated. Overall, patients found PRIDD to be comprehensible, comprehensive, relevant, acceptable, and feasible. Participants were able to discern the conceptual framework domains from the items. Feedback resulted in: the recall period being extended from 1 week to 1 month; removal of the ‘not relevant’ response option; and changes to the instructions and item ordering and wording to improve clarity and increase respondents’ confidence in their ability to respond. These evidence-based adjustments resulted in a 26-item version of PRIDD. CONCLUSION: This study met the gold-standard COSMIN criteria for the pilot testing of health measurement instruments. The data triangulated our previous findings, in particular the conceptual framework of impact. Our findings illuminate how patients understand and respond to PRIDD and other patient-reported measurement instruments. The results of comprehensibility, comprehensiveness, relevance, acceptability, and feasibility of PRIDD provide evidence of content validity from the target population. The next step in the development and validation of PRIDD is psychometric testing. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10196461/ /pubmed/37215711 http://dx.doi.org/10.3389/fmed.2023.1020523 Text en Copyright © 2023 Pattinson, Trialonis-Suthakharan, Hewitt, Valencia López, Tahmasebi Gandomkari, Austin, FitzGerald, Courtier, Augustin and Bundy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Pattinson, Rachael
Trialonis-Suthakharan, Nirohshah
Hewitt, Rachael M.
Valencia López, Maria José
Tahmasebi Gandomkari, Nasim
Austin, Jennifer
FitzGerald, Allison
Courtier, Nick
Augustin, Matthias
Bundy, Chris
Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure
title Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure
title_full Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure
title_fullStr Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure
title_full_unstemmed Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure
title_short Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure
title_sort evidence of the content validity, acceptability, and feasibility of a new patient-reported impact of dermatological diseases measure
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196461/
https://www.ncbi.nlm.nih.gov/pubmed/37215711
http://dx.doi.org/10.3389/fmed.2023.1020523
work_keys_str_mv AT pattinsonrachael evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT trialonissuthakharannirohshah evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT hewittrachaelm evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT valencialopezmariajose evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT tahmasebigandomkarinasim evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT austinjennifer evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT fitzgeraldallison evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT courtiernick evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT augustinmatthias evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure
AT bundychris evidenceofthecontentvalidityacceptabilityandfeasibilityofanewpatientreportedimpactofdermatologicaldiseasesmeasure